Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Expected currency impact for H2 and full year 2021 Currency impact vs. PY %pts, assuming mid-July exchange rates prevail in 2021 I 3 FX impact on Net sales 5 0 I I I FY Q1 Q2 I 2020 I Actual Simulation 37 Investor Relations | Q2 2021 Results 1 2 0 FX impact on Core operating income -4 Q3 Q4 FY FY I 2021 2020 I 5 3 2 to 3 1 to 2 0 to 1 Q1 Q2 Q3 Q4 FY 2021 1 NOVARTIS | Reimagining Medicine

View entire presentation